Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY Former Minister Nemoto to Initiate Debates on Pharma Policies by Young Lawmakers
January 19, 2023
-
BUSINESS Ex-Sandoz Japan Chief Tapped to Spearhead Nichi-Iko Turnaround
January 18, 2023
-
REGULATORY Ex-Minister Tamura Hightlights Need for Rewarding Innovation towards FY2024 Drug Reform
January 17, 2023
-
ORGANIZATION Japan Pharma Lobbies Look Set to Shift to Okada/Ueno Leadership towards FY2024 Reform
January 17, 2023
-
BUSINESS Alzheimer’s Med Lecanemab Submitted in Japan: Eisai
January 16, 2023
-
REGULATORY Experts Call for Deregulations for Orphan Support, English Dossiers to Foster Biotech Ecosystem
January 16, 2023
-
BUSINESS Daiichi Sankyo Files First Home-Developed mRNA COVID Vaccine in Japan
January 16, 2023
-
BUSINESS Janssen Vows to Offer New Positions for Employees Shown Exit Door: 1st Labor Talks
January 13, 2023
-
REGULATORY PMP, Off-Patent Drug Rules to Be Major Topics for 2024 Reform: MHLW Pharma Management Director
January 12, 2023
-
BUSINESS Eisai Files Alzheimer’s Med Lecanemab in Europe
January 12, 2023
-
ORGANIZATION FPMAJ Chief Poised to Push Rethink of Price Revision Rules towards FY2024 Reform
January 11, 2023
-
BUSINESS Leqembi Likely to Hit Peak Sales after 2030, US$26,500 Price Matches Value: Eisai CEO
January 10, 2023
-
BUSINESS Lecanemab Nabs Accelerated Approval in US, Set to Hit Market Late January
January 10, 2023
-
REGULATORY MHLW Eyes April Proposal to Push Generic Industry Shake-Up: Asst. Vice Minister
January 6, 2023
-
BUSINESS Japan Likely to See Generic Listing for Azilva, Zytiga in 2023; Xarelto AG Rivals Too
January 5, 2023
-
TRENDS Top 10 PHARMA JAPAN Articles in 2022
December 28, 2022
-
REGULATORY PMDA Says “Slow Cartagena Review” Is Urban Legend, Set to Dispel Misconception
December 27, 2022
-
REGULATORY Japan Approves Sanofi’s PD-1 Inhibitor, Teikoku’s Donepezil Tape and More
December 26, 2022
-
BUSINESS Janssen Labor Union to Hold 1st Bargaining Session as Early as Jan. 11
December 23, 2022
-
REGULATORY Special PMP Increase to Offset 95% of Price Cuts for 150 Products: FY2023 Revision
December 22, 2022
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…